Work

Fingolimod, a sphingosine-1-phosphate receptor modulator, prevents neonatal bronchopulmonary dysplasia and subsequent airway remodeling in a murine model

Year: 2024

Type: article

Abstract: The role of the S1P receptor1 modulator, fingolimod, as an FDA-approved drug in preventing the recurrence of multiple sclerosis is established. Fingolimod prevented bronchopulmonary dysplasia (BPD) and its sequela of airway remodeling in a neonatal murine model. This protection was associated with the downregulation of lysyl oxidase signaling pathway. Fingolimod could be repurposed for the therapy of BPD.

Source: Journal of Applied Physiology

DOI: 10.1152/japplphysiol.00311.2024

Authors: Tara Sudhadevi, Akanksha Annadi, Prathima Basa, Anjum Jafri, Viswanathan Natarajan, Anantha Harijith

Institutions: Case Western Reserve University, University of Illinois Chicago

Language: English

Topic: Neonatal Respiratory Health Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: American Heart Association, Eunice Kennedy Shriver National Institute of Child Health and Human Development